BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37436771)

  • 1. Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis.
    Abidi MZ; Molina KC; Garth K; Gutman JA; Weinberg A
    Transpl Infect Dis; 2023 Oct; 25(5):e14104. PubMed ID: 37436771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
    Hinman B; Cox J; Umoru G; Kamble R; Musick W
    Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis.
    Mori Y; Harada T; Yoshimoto G; Shima T; Numata A; Jinnouchi F; Yamauchi T; Kikushige Y; Kunisaki Y; Kato K; Takenaka K; Akashi K; Miyamoto T
    Int J Hematol; 2022 Aug; 116(2):258-265. PubMed ID: 35524024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
    Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
    Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus-Specific T Cells in Pediatric Liver Transplant Recipients.
    Getsuwan S; Apiwattanakul N; Lertudomphonwanit C; Hongeng S; Boonsathorn S; Manuyakorn W; Tanpowpong P; Anurathapan U; Tangnararatchakit K; Treepongkaruna S
    Viruses; 2023 Nov; 15(11):. PubMed ID: 38005890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.
    Mori Y; Jinnouchi F; Takenaka K; Aoki T; Kuriyama T; Kadowaki M; Odawara J; Ueno T; Kohno K; Harada T; Yoshimoto G; Takase K; Henzan H; Kato K; Ito Y; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Akashi K; Miyamoto T
    Bone Marrow Transplant; 2021 Apr; 56(4):853-862. PubMed ID: 33139867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
    Koch K; Osswald L; Miller I; Braitsch K; Götze K; Bassermann F; Herhaus P; Verbeek M
    Anticancer Res; 2022 Nov; 42(11):5431-5441. PubMed ID: 36288861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
    Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
    J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
    Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral/Cellular Immune Discordance in Stem Cell Donors: Impact on Cytomegalovirus-Specific Immune Reconstitution after Related Hematopoietic Transplantation.
    Valle-Arroyo J; Páez-Vega A; Fernández-Moreno R; López-Jiménez J; Luna A; Duarte R; Serrano-Martínez F; Villar S; Fernández-Alonso M; Reina G; González-Rico C; Fariñas MC; Rojas R; Herrera C; Martín C; García-Torres E; Torre-Cisneros J; Cantisán S
    Transplant Cell Ther; 2022 Oct; 28(10):703.e1-703.e8. PubMed ID: 35830929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
    Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
    Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
    Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
    Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
    Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
    Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis.
    Moore WJ; Boutin CA; Tanna S
    Curr Opin Infect Dis; 2023 Dec; 36(6):514-521. PubMed ID: 37773928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
    Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
    Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
    Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
    Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D
    Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.